Proline‑rich polypeptide‑1 decreases cancer stem cell population by targeting BAFF chromatin‑remodeling complexes in human chondrosarcoma JJ012 cells

Moran,Alexandra; Hoyt,Aaron; Sedani,Anil; Granger,Caroline; Saigh,Shannon; Blonska,Marzenna; Zhao‑Ju,Liu; Conway,Sheila Ann; Pretell,Juan; Brown,Jeffrey; Galoian,Karina

doi:10.3892/or.2020.7612

Proline‑rich polypeptide‑1 decreases cancer stem cell population by targeting BAFF chromatin‑remodeling complexes in human chondrosarcoma JJ012 cells

Authors:
- Alexandra Moran
- Aaron Hoyt
- Anil Sedani
- Caroline Granger
- Shannon Saigh
- Marzenna Blonska
- Liu Zhao‑Ju
- Sheila Ann Conway
- Juan Pretell
- Jeffrey Brown
- Karina Galoian
View Affiliations

Affiliations: Department of Orthopaedics, University of Miami, Miller School of Medicine, Miami, FL 33136, USA, Flow Cytometry Core Facility, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL 33136, USA, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL 33136, USA, Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL 33136, USA
Published online on: May 14, 2020 https://doi.org/10.3892/or.2020.7612
Pages: 393-403

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chondrosarcoma is the second most common primary malignant bone tumor and is resistant to chemotherapy and radiation. Inadequate treatment response and poor prognosis requires novel therapeutic approaches. Proline‑rich polypeptide‑1 (PRP‑1), synthesized by brain neurosecretory cells, has demonstrated antitumor properties in JJ012‑cells; however, its underlying molecular mechanism remains unclear. The present study aimed to investigate the epigenetic regulation by which PRP‑1 inhibits chondrosarcoma cancer stem cell (CSC) proliferation and to elucidate additional CSC biomarkers in human chondrosarcoma other than ALDH1A1. Human chondrosarcoma JJ012‑cells were treated with PRP‑1 prior to performing an Aldefluor™ assay and fluorescence‑activated cell sorting in order to determine aldehyde dehydrogenase (ALDH) expression levels and isolate ALDHhigh and ALDHlow cell populations. ALDH is an established marker of CSCs in several neoplasms, including chondrosarcoma. The cells were collected and lysed for gel electrophoresis, followed by western blot analysis. The Aldefluor™ assay was used to assess the expression levels of well‑established CSC biomarkers, including CD133, CD4, CD10, CD144, CD177, CD221, CD271, leucine‑rich repeat‑containing G protein‑coupled receptor 5, SOX2 and B lymphoma Mo‑MLV insertion region 1 homolog (BMI‑1), within the ALDHhigh population of JJ012 cells. The results confirmed that ALDHA1 was the biomarker for chondrosarcoma CSCs. PRP‑1 was demonstrated to inhibit the ALDHhigh population colony and sarcosphere formation; 5 µg/ml PRP‑1 was indicated to be the optimum concentration in eliminating colonies formed by JJ012 cells (92%, P<0.001) and by the ALDHhigh CSC‑population (80.5%, P<0.001) in the clonogenic dose‑response assay. Spheroid growth unequivocally decreased with an increase in PRP‑1 dose. In order to determine the molecular mechanism by which PRP‑1 decreased the CSC population, the regulation of the mammalian Switch/sucrose non‑fermenting (SWI/SNF) complex, also referred to as BRG1‑associated factor (BAF) complex, which either activates or represses transcription, thus acting as an oncogene or tumor suppressor in human cells, was analyzed. PRP‑1 was demonstrated to decrease the expression levels of BRG, BAF170 and BRM; therefore, in JJ012 cells, these key players of the SWI/SNF (BAF) complex served an oncogenic role. The results of the present study demonstrated that PRP‑1 targets chromatin‑remodeling complexes; therefore, future efforts will be directed towards determining the interconnection between CSC maintenance, self‑renewal capacity and BAF complexes.

View Figures

View References

1	Dorfman HD and Czerniak B: Bone cancers. Cancer. 75 (1 Suppl):S203–S210. 1995. View Article : Google Scholar
2	Fujiwara T and Ozaki T: Overcoming therapeutic resistance of bone sarcomas: Overview of the molecular mechanisms and therapeutic targets for bone sarcoma stem cells. Stem Cells Int. 2016:26030922016. View Article : Google Scholar : PubMed/NCBI
3	Galoian K, Qureshi A, D'Ippolito G, Schiller PC, Molinari M, Johnstone AL, Brothers SP, Paz AC and Temple HT: Epigenetic regulation of embryonic stem cell marker miR302C in human chondrosarcoma as determinant of antiproliferative activity of proline-rich polypeptide 1. Int J Oncol. 47:465–472. 2015. View Article : Google Scholar : PubMed/NCBI
4	Galoian K, Abrahamyan S, Chailyan G, Qureshi A, Patel P, Metser G, Moran A, Sahakyan I, Tumasyan N, Lee A, et al: Toll like receptors TLR1/2, TLR6 and MUC5B as binding interaction partners with cytostatic proline rich polypeptide 1 in human chondrosarcoma. Int J Oncol. 52:139–154. 2018.PubMed/NCBI
5	Vermeulen L, Todaro M, de Sousa Mello F, Sprick MR, Kemper K, Perez Alea M, Richel DJ, Stassi G and Medema JP: Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci USA. 105:13427–13432. 2008. View Article : Google Scholar : PubMed/NCBI
6	Sell S: On the stem cell origin of cancer. Am J Pathol. 176:2584–2494. 2010. View Article : Google Scholar : PubMed/NCBI
7	Honoki K, Fujii H, Kubo A, Kido A, Mori T, Tanaka Y and Tsujiuchi T: Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol Rep. 24:501–505. 2010. View Article : Google Scholar : PubMed/NCBI
8	Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y and Noguchi S: Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 15:4234–4241. 2009. View Article : Google Scholar : PubMed/NCBI
9	Awad O, Yustein JT, Shah P, Gul N, Katuri V, O'Neill A, Kong Y, Brown ML, Toretsky JA and Loeb DM: High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One. 5:e139432010. View Article : Google Scholar : PubMed/NCBI
10	Galoyan A: Neurochemistry of brain neuroendocrine immune system: Signal molecules. Neurochem Res. 25:1343–1355. 2000. View Article : Google Scholar : PubMed/NCBI
11	Galoian K, Temple TH and Galoyan A: Cytostatic effect of the hypothalamic cytokine PRP-1 is mediated by mTOR and cMyc inhibition in high grade chondrosarcoma. Neurochem Res. 36:812–818. 2011. View Article : Google Scholar : PubMed/NCBI
12	Galoian K, Qureshi A, Wideroff G and Temple HT: Restoration of desmosomal junction protein expression and inhibition of H3K9-specific histone demethylase activity by cytostatic proline-rich polypeptide-1 leads to suppression of tumorigenic potential in human chondrosarcoma cells. Mol Clin Oncol. 3:171–178. 2015. View Article : Google Scholar : PubMed/NCBI
13	Galoian K, Luo S, Qureshi A, Patel P, Price R, Morse AS, Chailyan G, Abrahamyan S and Temple HT: Effect of cytostatic proline rich polypeptide-1 on tumor suppressors of inflammation pathway signaling in chondrosarcoma. Mol Clin Oncol. 5:618–624. 2016. View Article : Google Scholar : PubMed/NCBI
14	Galoian KA, Guettouche T, Issac B, Qureshi A and Temple HT: Regulation of onco and tumor suppressor MiRNAs by mTORC1 inhibitor PRP-1 in human chondrosarcoma. Tumour Biol. 35:2335–2341. 2014. View Article : Google Scholar : PubMed/NCBI
15	Galoian KA, Temple TH and Galoyan A: Cytostatic effect of novel mTOR inhibitor, PRP-1 (galarmin) in MDA 231 (ER-) breast carcinoma cell line. PRP-1 inhibits mesenchymal tumors. Tumour Biol. 32:745–751. 2011. View Article : Google Scholar : PubMed/NCBI
16	Lohberger B, Rinner B, Stuendl N, Absenger M, Liegl- Atzwanger B, Walzer SM, Windhager R and Leithner A: Aldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcoma. PLoS One. 7:e436642012. View Article : Google Scholar : PubMed/NCBI
17	Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
18	Nakahata K, Uehara S, Nishikawa S, Kawatsu M, Zenitani M, Oue T and Okuyama H: Aldehyde dehydrogenase 1 (ALDH1) is a potential marker for cancer stem cells in embryonal rhabdomyosarcoma. PLoS One. 10:e01254542015. View Article : Google Scholar : PubMed/NCBI
19	Tolstorukov MY, Sansam CG, Lu P, Koellhoffer EC, Helming KC, Alver BH, Tillman EJ, Evans JA, Wilson BG, Park PJ and Roberts CW: Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters. Proc Natl Acad Sci USA. 110:10165–10170. 2013. View Article : Google Scholar : PubMed/NCBI
20	Ueda K, Ogasawara S, Akiba J, Nakayama M, Todoroki K, Ueda K, Sanada S, Suekane S, Noguchi M, Matsuoka K and Yano H: Aldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell line. PLoS One. 8:e754632013. View Article : Google Scholar : PubMed/NCBI
21	Hoyt AK, Moran A, Granger C, Sedani A, Saigh S, Brown J and Galoian KA: PRP1 significantly decreases the ALDHhigh cancer stem cell population and regulates the aberrant Wnt/β-catenin pathway in human chondrosarcoma JJ012 cells. Oncol Rep. 42:103–114. 2019.PubMed/NCBI
22	Kim WT and Ryu CJ: Cancer stem cell surface markers on normal stem cells. BMB Rep. 50:285–298. 2017. View Article : Google Scholar : PubMed/NCBI
23	Wirths S, Malenke E, Kluba T, Rieger S, Müller MR, Schleicher S, Hann von Weyhern C, Nagl F, Fend F, Vogel W, et al: Shared cell surface marker expression in mesenchymal stem cells and adult sarcomas. Stem Cells Transl Med. 2:53–60. 2013. View Article : Google Scholar : PubMed/NCBI
24	Genadry KC, Pietrobono S, Rota R and Linardic CM: Soft tissue sarcoma cancer stem cells: An overview. Front Oncol. 8:4752018. View Article : Google Scholar : PubMed/NCBI
25	Mak AB, Pehar M, Nixon AM, Williams RA, Uetrecht AC, Puglielli L and Moffat J: Post-translational regulation of CD133 by ATase1/ATase2-mediated lysine acetylation. J Mol Biol. 426:2175–2182. 2014. View Article : Google Scholar : PubMed/NCBI
26	Jacques C, Lamoureux F, Baud'huin M, Rodriguez Calleja L, Quillard T, Amiaud J, Tirode F, Rédini F, Bradner JE, Heymann D and Ory B: Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1. Oncotarget. 7:24125–24140. 2016. View Article : Google Scholar : PubMed/NCBI
27	Wang JC: Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol. 3:430–440. 2002. View Article : Google Scholar : PubMed/NCBI
28	Pulleyblank DE: Of topo and maxwell's dream. Science. 277:648–649. 1997. View Article : Google Scholar : PubMed/NCBI
29	Li TK and Liu LF: Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol. 41:53–77. 2001. View Article : Google Scholar : PubMed/NCBI
30	da Cunha IW, De Brot L, Carvalho KC, Rocha RM, Fregnani JH, Falzoni R, Ferreira Fde O, Aguiar S Jr, Lopes A, Muto NH, et al: Prognostication of soft tissue sarcomas based on chromosome 17q gene and protein status: Evaluation of TOP2A, HER-2/neu, and survivin. Ann Surg Oncol. 19:1790–1799. 2012. View Article : Google Scholar : PubMed/NCBI
31	Baiocchi G, Poliseli FL, De Brot L, Mantoan H, Schiavon BN, Faloppa CC, Vassallo J, Soares FA and Cunha IW: TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma. J Clin Pathol. 69:884–889. 2016. View Article : Google Scholar : PubMed/NCBI
32	Raab JR, Runge JS, Spear CC and Magnuson T: Co-regulation of transcription by BRG1 and BRM, two mutually exclusive SWI/SNF ATPase subunits. Epigenetics Chromatin. 10:622017. View Article : Google Scholar : PubMed/NCBI
33	Douglas D, Hsu JH, Hung L, Cooper A, Abdueva D, van Doorninck J, Peng G, Shimada H, Triche TJ and Lawlor ER: BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression. Cancer Res. 68:6507–6515. 2008. View Article : Google Scholar : PubMed/NCBI
34	Pietersen AM, Horlings HM, Hauptmann M, Langerød A, Ajouaou A, Cornelissen-Steijger P, Wessels LF, Jonkers J, van de Vijver MJ and van Lohuizen M: EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res. 10:R1092008. View Article : Google Scholar : PubMed/NCBI
35	Dhawan S, Tschen SI and Bhushan A: Bmi-1 regulates the Ink4a/Arf locus to control pancreatic beta-cell proliferation. Genes Dev. 23:906–911. 2009. View Article : Google Scholar : PubMed/NCBI
36	Becker M, Korn C, Sienerth AR, Voswinckel R, Luetkenhaus K, Ceteci F and Rapp UR: Polycomb group protein Bmi1 is required for growth of RAF driven non-small-cell lung cancer. PLoS One. 4:e42302009. View Article : Google Scholar : PubMed/NCBI
37	Dovey JS, Zacharek SJ, Kim CF and Lees JA: Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion. Proc Natl Acad Sci USA. 105:11857–11862. 2008. View Article : Google Scholar : PubMed/NCBI
38	Bruggeman SW, Hulsman D, Tanger E, Buckle T, Blom M, Zevenhoven J, van Tellingen O and van Lohuizen M: Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell. 12:328–341. 2007. View Article : Google Scholar : PubMed/NCBI
39	Wang E, Bhattacharyya S, Szabolcs A, Rodriguez-Aguayo C, Jennings NB, Lopez-Berestein G, Mukherjee P, Sood AK and Bhattacharya R: Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One. 6:e179182011. View Article : Google Scholar : PubMed/NCBI
40	Hsu JH and Lawlor ER: BMI 1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma. Oncogene. 30:2077–2085. 2011. View Article : Google Scholar : PubMed/NCBI
41	Wu Z, Min L, Chen D, Hao D, Duan Y, Qiu G and Wang Y: Overexpression of BMI-1 promotes cell growth and resistance to cisplatin treatment in osteosarcoma. PLoS One. 6:e146482011. View Article : Google Scholar : PubMed/NCBI
42	Liu L, Andrews LG and Tollefsbol TO: Loss of the human polycomb group protein BMI1 promotes cancer-specific cell death. Oncogene. 25:4370–4375. 2006. View Article : Google Scholar : PubMed/NCBI
43	Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C, Theilgaard-Mönch K, Minucci S, Porse BT, Marine JC, et al: The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 21:525–530. 2007. View Article : Google Scholar : PubMed/NCBI
44	Liu W, Stein P, Cheng X, Yang W, Shao NY, Morrisey EE, Schultz RM and You J: BRD4 regulates Nanog expression in mouse embryonic stem cells and preimplantation embryos. Cell Death Differ. 21:1950–1960. 2014. View Article : Google Scholar : PubMed/NCBI
45	Gonzales-Cope M, Sidoli S, Bhanu NV, Won KJ and Garcia BA: Histone H4 acetylation and the epigenetic reader Brd4 are critical regulators of pluripotency in embryonic stem cells. BMC Genomics. 17:952016. View Article : Google Scholar : PubMed/NCBI
46	Rahnamoun H, Lee J, Sun Z, Lu H, Ramsey KM, Komives EA and Lauberth SM: RNAs interact with BRD4 to promote enhanced chromatin engagement and transcription activation. Nat Struct Mol Biol. 25:687–697. 2018. View Article : Google Scholar : PubMed/NCBI
47	Zhang HT, Gui T, Sang Y, Yang J, Li YH, Liang GH, Li T, He QY and Zha ZG: The BET bromodomain inhibitor JQ1 suppresses chondrosarcoma cell growth via regulation of YAP/p21/c-Myc signaling. J Cell Biochem. 118:2182–2192. 2017. View Article : Google Scholar : PubMed/NCBI
48	McBride MJ and Kadoch C: Disruption of mammalian SWI/SNF and polycomb complexes in human sarcomas: Mechanisms and therapeutic opportunities. J Pathol. 244:638–649. 2018. View Article : Google Scholar : PubMed/NCBI
49	De-Meng Chen X-QZ, Kai Wang and Yi-Zhou Jiang: SWI/SNF chromatin remodeling complex in regulating mesenchymal stem cell lineage specification. J Tissue Sci Engineering. 6:1542015.
50	Yang J, Ren Z, Du X, Hao M and Zhou W: The role of mesenchymal stem/progenitor cells in sarcoma: Update and dispute. Stem Cell Investig. 1:182014.PubMed/NCBI
51	Tang L, Nogales E and Ciferri C: Structure and function of SWI/SNF chromatin remodeling complexes and mechanistic implications for transcription. Prog Biophys Mol Biol. 102:122–128. 2010. View Article : Google Scholar : PubMed/NCBI
52	Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, Cho YJ, Koellhoffer EC, Pomeroy SL, Orkin SH and Roberts CW: Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell. 18:316–328. 2010. View Article : Google Scholar : PubMed/NCBI
53	de Andrea CE and Hogendoorn PC: Epiphyseal growth plate and secondary peripheral chondrosarcoma: The neighbours matter. J Pathol. 226:219–228. 2012. View Article : Google Scholar : PubMed/NCBI
54	Kadoch C, Williams RT, Calarco JP, Miller EL, Weber CM, Braun SM, Pulice JL, Chory EJ and Crabtree GR: Dynamics of BAF-Polycomb complex opposition on heterochromatin in normal and oncogenic states. Nat Genet. 49:213–222. 2017. View Article : Google Scholar : PubMed/NCBI
55	Shao Z, Raible F, Mollaaghababa R, Guyon JR, Wu CT, Bender W and Kingston RE: Stabilization of chromatin structure by PRC1, a Polycomb complex. Cell. 98:37–46. 1999. View Article : Google Scholar : PubMed/NCBI
56	Poynter ST and Kadoch C: Polycomb and trithorax opposition in development and disease. Wiley Interdiscip Rev Dev Biol. 5:659–688. 2016. View Article : Google Scholar : PubMed/NCBI
57	Zhang X, Li B, Li W, Ma L, Zheng D, Li L, Yang W, Chu M, Chen W, Mailman RB, et al: Transcriptional repression by the BRG1-SWI/SNF complex affects the pluripotency of human embryonic stem cells. Stem Cell Reports. 3:460–474. 2014. View Article : Google Scholar : PubMed/NCBI
58	Kahali B, Yu J, Marquez SB, Thompson KW, Liang SY, Lu L and Reisman D: The silencing of the SWI/SNF subunit and anticancer gene BRM in Rhabdoid tumors. Oncotarget. 5:3316–3332. 2014. View Article : Google Scholar : PubMed/NCBI
59	Fulda S and Kogel D: Cell death by autophagy: Emerging molecular mechanisms and implications for cancer therapy. Oncogene. 34:5105–5113. 2015. View Article : Google Scholar : PubMed/NCBI
60	Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y and Kondo S: Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 11:448–457. 2004. View Article : Google Scholar : PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI PubMed/NCBI